MLAB
Mesa Laboratories Inc /Co/One customer — 20% of revenue (fiscal 2026)
“In our Clinical Genomics division, a significant portion of revenues is generated from ongoing purchases by a relatively small number of established customers, with a single customer accounting for approximately 20% of the division's revenues in fiscal 2026.”
Price & Indicators
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| AOI as a percentage of revenues non-GAAP | 25.5% | FY2026 | — |
| AOI per diluted share of common stock non-GAAP | $10.72 | FY2026 | — |
| Free cash flow non-GAAP | 39,581K | FY2026 | — |
| Non-GAAP adjusted operating income excluding unusual items non-GAAP | 63,487K | FY2026 | — |
| Total Net Leverage Ratio | 2.11 | as of March 31, 2026 | — |
| Organic Revenues Growth non-GAAP | 3.7% | Nine Months Ended December 31, 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Scientific & Technical Instruments — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MLAB
this stock
Mesa Laboratories Inc /Co/
|
$523.10M | +20.8% | +2.7% | 78.3 | 5.0% |
|
COHR
Coherent Corp.
|
$57.95B | +62.2% | +19.2% | 140.4 | 4.4% |
|
KEYS
Keysight Technologies, Inc.
|
$55.15B | +58.8% | +8.0% | 52.9 | 1.8% |
|
GRMN
Garmin Ltd
|
$46.65B | +19.6% | +15.1% | 27.0 | 2.2% |
|
TDY
Teledyne Technologies Inc
|
$28.92B | +22.2% | +24.1% | 31.6 | 3.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MLAB | +3.6% | -9.0% | +9.7% | -4.9% | +20.8% |
| SPY | +1.3% | -0.2% | +10.1% | +1.1% | +10.7% |
| vs SPY | +2.4% | -8.9% | -0.4% | -6.0% | +10.1% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.